Loading financials from SEC filings…
Chemicals · Basic Materials · Fiscal year ends Dec 31
Chemours reported revenue of $5.8B in the fiscal year ended Dec 2025, up 0.4% from the year before. Net income was −$386M. Operating cash flow of $264M less capital expenditure of $213M left free cash flow of $51M. Net debt was $3.5B.
Ranks among the 18 chemicals companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6,345 | 6,831 | 6,078 | 5,782 | 5,808 |
| Cost of revenue | 4,964 | 5,215 | 4,776 | 4,640 | 4,906 |
| Gross profit | 1,381 | 1,616 | 1,302 | 1,142 | 902 |
| Research & development | 107 | 118 | 108 | 109 | 108 |
| Selling, general & admin | 592 | 710 | 1,286 | 598 | 799 |
| Interest expense | 185 | 163 | 208 | 263 | 269 |
| Pre-tax income | 676 | 741 | −318 | 106 | −277 |
| Income tax | 68.0 | 163 | −66.0 | 37.0 | 109 |
| Net income | 608 | 578 | −253 | 69.0 | −386 |
| Diluted EPS | 3.60 | 3.65 | −1.70 | 0.46 | −2.57 |
| Diluted shares | 169 | 158 | 149 | 150 | 150 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 1,451 | 1,102 | 1,203 | 713 | 670 |
| Receivables | 644 | 509 | 509 | 619 | 562 |
| Inventory | 1,099 | 1,404 | 1,349 | 1,463 | 1,569 |
| Current assets | 3,345 | 3,214 | 3,844 | 3,017 | 3,001 |
| Net PP&E | 3,154 | 3,171 | 3,207 | 3,188 | 3,078 |
| Goodwill | 102 | 102 | 102 | 46.0 | 46.0 |
| Total assets | 7,550 | 7,640 | 8,241 | 7,509 | 7,382 |
| Payables | 1,162 | 1,233 | 1,159 | 1,156 | 954 |
| Deferred revenue | 3.0 | 5.0 | 16.0 | 11.0 | 5.0 |
| Current liabilities | 1,858 | 1,891 | 2,487 | 1,820 | 1,686 |
| Short-term debt | 25.0 | 43.0 | 51.0 | 54.0 | 42.0 |
| Long-term debt | 3,724 | 3,590 | 3,989 | 4,059 | 4,099 |
| Total liabilities | 6,468 | 6,533 | 7,518 | 6,937 | 7,131 |
| Shareholders' equity | 1,081 | 1,107 | 721 | 571 | 250 |
| Backlog (remaining obligations) | – | – | – | 272 | 180 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | 814 | 755 | 556 | −633 | 264 |
| Capital expenditure | 277 | 307 | 370 | 360 | 213 |
| Free cash flow | 537 | 448 | 186 | −993 | 51.0 |
| Depreciation & amortisation | 317 | 291 | 309 | 292 | 340 |
| Stock-based compensation | 34.0 | 27.0 | 18.0 | 15.0 | 21.0 |
| Acquisitions | 0.0 | – | – | – | – |
| Share buybacks | 173 | 495 | 69.0 | – | – |
| Dividends paid | 164 | 154 | 149 | 148 | 78.0 |
| Dividend per share | 1.00 | 1.00 | 1.00 | 1.00 | 0.51 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | 7.7% | −11.0% | −4.9% | 0.4% |
| EPS growth (YoY) | – | 1.4% | −146.6% | – | −658.7% |
| Gross margin | 21.8% | 23.7% | 21.4% | 19.8% | 15.5% |
| Net margin | 9.6% | 8.5% | −4.2% | 1.2% | −6.6% |
| Return on equityBlank when equity is negative | 56.2% | 52.2% | −35.1% | 12.1% | −154.4% |
| Free cash flow margin | 8.5% | 6.6% | 3.1% | −17.2% | 0.9% |
| Cash conversion (CFO ÷ net income) | 1.34x | 1.31x | −2.20x | −9.17x | −0.68x |
| Receivable days | 37 | 27 | 31 | 39 | 35 |
| Inventory days | 81 | 98 | 103 | 115 | 117 |
| Payable days | 85 | 86 | 89 | 91 | 71 |
| Debt ÷ equity | 3.47x | 3.28x | 5.60x | 7.20x | 16.6x |
| Net debtDebt − cash & equivalents; excludes investments; negative = net cash | 2,298 | 2,531 | 2,837 | 3,400 | 3,471 |
| Current ratio | 1.80x | 1.70x | 1.55x | 1.66x | 1.78x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.